MedTrace Logo

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

FT538

FT538 is an allogeneic natural killer (NK)-cell immunotherapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

COMBINATION_PRODUCT

Monoclonal antibody - Dose Escalation

either avelumab, trastuzumab or cetuximab

COMBINATION_PRODUCT

Monoclonal antibody - Dose Expansion

either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2023-08-11
Completion
2023-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05069935 on ClinicalTrials.gov